Product Description
a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18983233/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | China | Colombia | Croatia | Dominican Republic | Egypt | Estonia | Germany | Hong Kong | Hungary | India | Italy | Japan | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2018-000663-80 |
2018-000663-80 | P3 |
Active, not recruiting |
Oncology Unspecified |
2019-05-11 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/08/2025 |
News Article |
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile |
|
10/10/2024 |
News Article |
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids |
|
09/23/2024 |
News Article |
Avenacy to Share Company's Year One Progress at CPHI Milan 2024 |
|
07/29/2024 |
News Article |
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags |